485 related articles for article (PubMed ID: 20588175)
21. Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.
Alharbi AM; De Marzo AM; Hicks JL; Lotan TL; Epstein JI
Am J Surg Pathol; 2018 Oct; 42(10):1286-1296. PubMed ID: 29944471
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
24. Skene's Gland Derivatives in the Female Genital Tract and Cervical Adenoid Basal Carcinoma are Consistently Positive With Prostatic Marker NKX3.1.
Hawari R; Fernandes L; Park KJ; McCluggage WG
Int J Gynecol Pathol; 2021 Jul; 40(4):400-407. PubMed ID: 33021555
[TBL] [Abstract][Full Text] [Related]
25. NKX3.1 expression in cervical 'adenoid basal cell carcinoma': another gynaecological lesion with prostatic differentiation?
Stewart CJR; Moses J
Pathology; 2021 Feb; 53(2):193-198. PubMed ID: 33032811
[TBL] [Abstract][Full Text] [Related]
26. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
27. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
28. Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Parwani AV; Kronz JD; Genega EM; Gaudin P; Chang S; Epstein JI
Am J Surg Pathol; 2004 May; 28(5):651-7. PubMed ID: 15105655
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features.
Nguyen JK; Chen YY; Magi-Galluzzi C; McKenney JK
Am J Surg Pathol; 2020 Dec; 44(12):1635-1642. PubMed ID: 32991340
[TBL] [Abstract][Full Text] [Related]
30. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas.
Garudadri G; Rao BV; Sundaram C; Fonseca D; Murthy SS; Sharma R; Rao TS
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S18-S24. PubMed ID: 32108621
[TBL] [Abstract][Full Text] [Related]
32. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry.
van Krieken JH
Am J Surg Pathol; 1993 Apr; 17(4):410-4. PubMed ID: 7684204
[TBL] [Abstract][Full Text] [Related]
33. ANXA7 expression represents hormone-relevant tumor suppression in different cancers.
Srivastava M; Torosyan Y; Raffeld M; Eidelman O; Pollard HB; Bubendorf L
Int J Cancer; 2007 Dec; 121(12):2628-36. PubMed ID: 17708571
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
35. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
[TBL] [Abstract][Full Text] [Related]
36. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A; Frouin E; Irani J; Fromont G; Levillain P
Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142
[TBL] [Abstract][Full Text] [Related]
37. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
38. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall.
Wobker SE; Khararjian A; Epstein JI
Am J Surg Pathol; 2017 Apr; 41(4):557-563. PubMed ID: 28291125
[TBL] [Abstract][Full Text] [Related]
39. Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies.
Gentile PS; Carloss HW; Huang TY; Yam LT; Lam WK
Cancer; 1988 Aug; 62(4):711-5. PubMed ID: 2456142
[TBL] [Abstract][Full Text] [Related]
40. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
